Inicio>>Signaling Pathways>> Others>>BRD4770

BRD4770 (Synonyms: HMTase Inhibitor VI)

Catalog No.GC10259

BRD4770 es un inhibidor de la histona metiltransferasa G9a. BRD4770 reduce la dimetilaciÓn y la trimetilaciÓn de la lisina 9 en la histona H3 (H3K9) con una CE50 de 5 μM y tiene un efecto menor o menor hacia H3K27me3, H3K36me3, H3K4me3 y H3K79me3. BRD4770 puede activar la vÍa mutada de ataxia telangiectasia (ATM) e inducir la senescencia celular.

Products are for research use only. Not for human use. We do not sell to patients.

BRD4770 Chemical Structure

Cas No.: 1374601-40-7

Tamaño Precio Disponibilidad Cantidad
10mg
99,00 $
Ship Within 10-14 Days
50mg
314,00 $
Ship Within 10-14 Days
100mg
451,00 $
Ship Within 10-14 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BRD4770 is a novel G9a(EHMT2) inhibitor with EC50 of 5 uM (trimethylated H3K9 in PANC-1 cell).IC50 value: 5 uM (PANC-1 cell) [1]Target: G9a inhibitorBRD4770 activates the ATM pathway without inducing DNA damage, while the ATR pathway is not affected. BRD4770 is a novel probe for studying G9a and its role in cellular senescence.Treatment of 5 μM BRD4770 for 24 h decreased H3K9 trimethylation level by 23% in PANC-1 cells. BRD9539 also inhibits PRC2 activity.

References:
[1]. Yuan Y, et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7.

Reseñas

Review for BRD4770

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BRD4770

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.